About This Fund
Vivo Opportunity Fund III is the latest iteration of Vivo Capital's evergreen equity fund, structured in three-year investment cycles. With over $740 million in commitments, the fund continues its focus on small- and mid-cap biotechnology and life sciences companies, particularly those developing or commercializing novel therapies targeting unmet medical needs. The fund primarily backs preclinical and clinical-stage companies, aiming to realize value through scientific breakthroughs and pivotal clinical milestones. Vivo Capital employs a hybrid strategy that combines public market investing with a venture capital approach, leveraging the firm’s technical expertise to identify high-potential healthcare assets. Vivo has a strong track record, with previous Opportunity Funds supporting companies that have reached major inflection points, such as FDA approvals or strategic acquisitions. Noteworthy examples include investments in Verona Pharmaceuticals, Geron Corporation, and Soleno Therapeutics.